Please set your featured image
OGT expands Next Generation Sequencing portfolio
3 August 2015: Oxford Gene Technology (OGT), the molecular genetics company, has announced the expansion of its portfolio of high-quality products for Next Generation Sequencing (NGS) with the addition of the SureSeq™ Ovarian Cancer Panel & SureSeq NGS Library Preparation Kit.
The new products are a result of significant recent investment of OGT’s R&D and commercial capabilities in the area, and will add to OGT’s existing range of NGS products, including the SureSeq Solid Tumour Panel, and the SureSeq Myeloid Panel, which was launched in June. OGT has worked closely with industry-leading experts to ensure the products have the most relevant and up-to-date content combined with simple and streamlined workflows.
Mike Evans, CEO of OGT commented, “NGS is a significant area of growth within the genomics industry and our strategic focus has been directed at driving forward new product development and sales. We have launched three new NGS products this year, and we are generating a strong pipeline of additional products in development.”
Find out more about the OGT’s expanding portfolio of SureSeq NGS products at www.ogt.com/sureseq.
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. OGT is based at Oxford University Begbroke Science Park.
For more information on the Company, please visit our website at www.ogt.com.